HBOT for Pain & Inflammation: Fibromyalgia, Migraines & More

What This Page Covers

A 2023 systematic review in BMJ Open found HBOT significantly reduced pain in fibromyalgia patients across 9 studies (288 patients). For migraines, a small but controlled trial showed a 50% reduction in attack frequency. For complex regional pain syndrome, case series report meaningful improvement in patients who had failed conventional treatment. The evidence varies by condition, but the biological mechanism is consistent: HBOT reduces neuroinflammation and modulates central sensitization.

This page is a hub for all of our in-depth articles on HBOT and pain-related conditions. Each condition below gets a brief summary of the evidence, with a link to the full article where we go deeper into the research, protocols, and practical considerations. We also point to our general resources on HBOT costs, side effects, and the broader research landscape.

A note on expectations: HBOT is not a painkiller in the conventional sense. It does not block pain signals in the short term the way an analgesic does. Its value in pain management comes from addressing upstream causes of pain, including hypoxic tissue, central sensitization, and unresolved inflammation. This means the research timelines are longer and the effects are sometimes subtle, but the potential for durable improvement is also greater than symptom suppression alone.

How Does HBOT Work for Pain & Inflammation?

Pain that persists beyond the resolution of an acute injury is driven by a different set of mechanisms than acute pain. Central sensitization, where the nervous system becomes upregulated and amplifies pain signals even in the absence of ongoing tissue damage, is a major component of conditions like fibromyalgia. Neuroinflammation in the spinal cord and brain contributes to this sensitization. HBOT reduces neuroinflammation through several pathways, including suppression of pro-inflammatory cytokines and activation of anti-inflammatory genetic cascades mediated by HIF-1-alpha and Nrf2. There is real biological rationale for why chronic pain patients may benefit.

In tissue-based pain (injuries, structural damage, compromised healing), HBOT works more directly. Pressurized oxygen saturates plasma and tissue fluid, delivering oxygen to areas of poor vascular supply where conventional circulation cannot reach. This accelerates the cellular machinery of repair: collagen synthesis, fibroblast proliferation, and angiogenesis (the formation of new blood vessels). For a broader overview of the published research base supporting HBOT, see our HBOT research hub.

What a Course of Treatment Looks Like

For chronic pain conditions, HBOT is not a single-session therapy. The research protocols that showed the clearest results in fibromyalgia and neuropathy typically involved 40 sessions, five days per week over eight weeks, at pressures of 2.0 ATA or higher. Each session lasts approximately 90 minutes inside a hard-shell hyperbaric chamber. Most patients report little discomfort beyond the sensation of ear pressure during descent, which is managed using the same techniques as airplane travel.

Some patients notice changes early in a treatment course. Others see meaningful improvement only in the final third of a protocol, or in the weeks after completion. This pattern is consistent with the underlying biology: rebuilding vascular networks and reducing central sensitization takes time, and the neurological changes driven by HBOT can continue to unfold after the sessions themselves are done.

It is worth being realistic about what improvement looks like. HBOT for fibromyalgia, even in the most positive trials, produced significant but not complete pain reduction in the majority of participants. Patients should enter treatment with clear expectations and ideally a way to measure their baseline (pain diaries, functional assessments, validated questionnaires) so that progress can be evaluated objectively rather than by impression alone.

Conditions Covered

Fibromyalgia

Fibromyalgia is among the best-studied pain conditions in the context of HBOT. A landmark randomized controlled trial published in PLOS ONE by Efrati et al. showed that 40 sessions of HBOT at 2.0 ATA led to significant reductions in pain intensity and tender points, along with measurable changes on SPECT brain imaging, suggesting genuine neurological change rather than placebo effect. These findings have been partially replicated in subsequent work. The evidence here is stronger than for most other off-label HBOT applications. Read the full review in our article on HBOT for fibromyalgia.

Migraines

HBOT has been used as an acute abortive treatment for migraine attacks since the 1980s. Studies show that breathing high-dose oxygen during a migraine attack, even at normal atmospheric pressure, can terminate attacks in a significant proportion of patients. HBOT at pressure may offer faster or more complete relief, though the research is largely older and the methodological quality is variable. The use of HBOT for migraine prevention, as opposed to acute treatment, is less well-established. Our article on HBOT for migraines covers both acute and preventive uses with honest commentary on the evidence.

Neuropathy

Peripheral neuropathy, whether from diabetes, chemotherapy, or other causes, involves nerve damage driven partly by ischemia and oxidative stress. HBOT’s ability to increase oxygen delivery to peripheral nerves and reduce oxidative damage pathways makes it a logical candidate. Clinical studies in diabetic peripheral neuropathy have shown improvements in nerve conduction velocity and pain scores in some trials. Evidence is moderate and not yet sufficient to recommend HBOT as a standard treatment, but the results are consistently positive in the right patient population. Read more in our article on HBOT for neuropathy.

Ligament and Soft Tissue Damage

Ligament injuries are notoriously slow to heal because ligaments have poor vascular supply under normal conditions. HBOT addresses this directly by raising oxygen levels in hypoperfused tissue, stimulating fibroblast activity and collagen synthesis. Research in this area is largely from sports medicine, where athletes use HBOT to accelerate return-to-play timelines. The evidence is encouraging, particularly for partial tears and post-surgical ligament repair. See our full article on HBOT for ligament damage for details on protocols and realistic timelines.

Bone Repair

HBOT is FDA-cleared for osteoradionecrosis (bone death caused by radiation) and has a well-established role in supporting bone healing in compromised patients. More broadly, HBOT stimulates osteoblast activity, improves bone graft integration, and supports healing in fractures with poor blood supply. Athletes and orthopedic patients use HBOT for faster recovery from stress fractures and complex breaks. The evidence for HBOT in standard bone repair is supportive, though it is used more as an adjunct to conventional treatment than a standalone therapy. Our article on HBOT for bone repair covers both the medical and athletic contexts.

How Do You Find the Right HBOT Clinic?

Not all hyperbaric facilities are equally suited for chronic pain applications. Hospital-based hyperbaric programs are often focused almost exclusively on wound care and approved indications, and may be less experienced with the 40-session neurological protocols used in fibromyalgia and neuropathy research. Independent HBOT clinics with experience in off-label neurological and pain applications may be better equipped to implement the right protocol, monitor your response, and adjust treatment parameters based on how you are responding. Ask prospective facilities how many patients they have treated for your specific condition, what protocol they use, and whether they have physicians on staff who can oversee your course of treatment rather than delegating entirely to technicians.

What to Discuss With Your Doctor

If you have chronic pain and are considering HBOT, the conversation with your physician should start with mechanism: what is driving your pain? HBOT is most likely to help when there is a clear component of inflammation, tissue hypoxia, or impaired healing. If your pain is primarily structural (a pinched nerve from a herniated disc, for example) HBOT alone is unlikely to resolve it, though it may reduce inflammatory contributions.

Ask about the pressure and number of sessions used in the research most relevant to your condition. Fibromyalgia trials typically used 2.0 ATA for 40 sessions. Acute migraine treatment uses different parameters. Matching your protocol to the research is important because mild hyperbaric (soft-shell chambers at 1.3 ATA) operates well below the pressures used in most published pain studies.

Be aware of the cost commitment. Forty sessions at a clinical HBOT facility typically cost between $4,000 and $10,000 out of pocket for off-label indications. See our hyperbaric chamber cost guide for a more detailed breakdown. Also review potential side effects of hyperbaric oxygen therapy before starting, particularly if you have conditions affecting the ears, lungs, or vision.

Related HBOT Guides

Pain and tissue recovery are closely linked. If you’re dealing with post-surgical pain or sports injuries, the guide on HBOT for surgery and wound recovery covers the healing side of that picture. For background on pressures, chamber types, and how HBOT produces its effects, the complete hyperbaric chamber guide is a good starting point.

References

1. Efrati S, et al. “Hyperbaric Oxygen Therapy Can Diminish Fibromyalgia Syndrome.” PLoS ONE. 2015;10(5):e0127012. DOI: 10.1371/journal.pone.0127012
2. Myers D, Myers RA. “A Preliminary Report on Hyperbaric Oxygen in the Relief of Migraine Headache.” Headache. 1995;35(4):197-199. DOI: 10.1111/j.1526-4610.1995.hed3504197.x
3. Bennett MH, et al. “Normobaric and hyperbaric oxygen therapy for migraine and cluster headache.” Cochrane Database Syst Rev. 2008. PMID: 18843617.
4. Atzeni F, et al. “Hyperbaric oxygen treatment of fibromyalgia: a prospective observational clinical study.” Clin Exp Rheumatol. 2019. PMID: 30747099
5. Fang J, et al. “Clinical efficacy and mechanisms of HBOT in rheumatic and immune diseases.” Front Med. 2025. DOI: 10.3389/fmed.2025.1706637

Seph Fontane Pennock

Author

Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.

Website